Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HEMEL HEMPSTEAD, England, March 27, 2017 -- (Healthcare Sales & Marketing Network) --EUSA Pharma today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in favour of marketin... Biopharmaceuticals, Oncology, Regulatory EUSA Pharma, Dinutuximab beta, neuroblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Neuroblastoma | Neurology | Pharmaceuticals